Last reviewed · How we verify
DAPT strategy
DAPT (Dual Antiplatelet Therapy) strategy involves the concurrent use of two antiplatelet agents to prevent thrombotic events in cardiovascular disease.
DAPT (Dual Antiplatelet Therapy) strategy involves the concurrent use of two antiplatelet agents to prevent thrombotic events in cardiovascular disease. Used for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI), Secondary prevention of thrombotic events post-PCI with stent placement, Stable coronary artery disease management.
At a glance
| Generic name | DAPT strategy |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Antiplatelet therapy combination |
| Target | P2Y12 receptor and cyclooxygenase (COX) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
DAPT typically combines aspirin with a P2Y12 inhibitor (such as clopidogrel, prasugrel, or ticagrelor) to provide synergistic antiplatelet effects. This dual approach reduces platelet aggregation through different mechanisms, lowering the risk of stent thrombosis and recurrent ischemic events in patients undergoing percutaneous coronary intervention or with acute coronary syndromes.
Approved indications
- Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI)
- Secondary prevention of thrombotic events post-PCI with stent placement
- Stable coronary artery disease management
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Dyspepsia
- Bruising
- Thrombotic thrombocytopenic purpura (TTP)
Key clinical trials
- The 10-Year Extended Follow-up of the DACAB Trial
- Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (PHASE3)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
- DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid (NA)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- A Polypill for Acute Coronary Syndrome (PHASE2)
- Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM) (NA)
- Ticagrelor De-escalation Strategy in AMI Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DAPT strategy CI brief — competitive landscape report
- DAPT strategy updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI